Convert Catalysts Into Profits: Sagient Research's Edward Stopke

The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner.

http://ift.tt/1Jt5vv4